We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

17 Jun 2026 - 19 Jun 2026

Lowering Cholesteryl Ester Levels Reduces Tau Tangles

By LabMedica International staff writers
Posted on 07 Feb 2019
An excess of cholesteryl esters, the storage product for excess cholesterol within cells, was shown to induce tau protein in neurons to form abnormal aggregates called neurofibrillary tangles that are characteristic of Alzheimer's disease.

Previous studies have determined that predisposition to Alzheimer’s disease (AD) may arise from altered cholesterol metabolism, although the molecular pathways that may link cholesterol to AD phenotypes are only partially understood.

In this regard, investigators at the University of California, San Diego (USA) performed a phenotypic screen for phosphorylated tau (pTau) accumulation in AD-patient iPSC (induced pluripotent stem cell)-derived neurons, which carried mutations in the cholesterol-binding domain of (Amyloid precursor protein) APP or lacked APP altogether.

The investigators reported in the January 24, 2019, online edition of the journal Cell Stem Cell that they had identified cholesteryl esters as upstream regulators of tau during early AD development. More...
They also found that while cholesteryl esters regulated Abeta secretion, their effects on tau and Abeta were mediated by independent pathways.

Efficacy and toxicity screening in iPSC-derived astrocytes and neurons showed that allosteric activation of the neuronal enzyme CYP46A1 lowered cholesteryl ester levels specifically in neurons and was well tolerated by astrocytes. Thus, cholesteryl esters were found to independently regulate tau and Abeta and could be reduced by a drug such as the anti-HIV drug efavirenz, which activates CYP46A1 and thereby reduces tau in AD-patient neurons.

“Our findings reveal that cholesteryl esters act on tau, which means more options and new possibilities for therapeutic intervention,” said senior author Dr. Lawrence S.B. Goldstein, professor of cellular and molecular medicine at the University of California, San Diego. “Identification of the CYP46A1-cholesteryl ester-tau axis means we have a druggable target and a potential therapeutic pathway in early AD.”

Related Links:
University of California, San Diego


Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Pipette Calibration System
Artel PCS®
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.